Lantheus (NASDAQ:LNTH) Price Target Lowered to $112.00 at JMP Securities

Lantheus (NASDAQ:LNTH) had its price objective cut by JMP Securities from $125.00 to $112.00 in a research note released on Thursday,Benzinga reports. They currently have a market outperform rating on the medical equipment provider’s stock.

A number of other brokerages have also commented on LNTH. B. Riley boosted their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Truist Financial lowered their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Leerink Partners lifted their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Finally, Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Price Performance

Shares of Lantheus stock traded down $0.81 on Thursday, reaching $87.50. 1,618,137 shares of the stock were exchanged, compared to its average volume of 993,186. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus has a one year low of $50.20 and a one year high of $126.89. The firm has a market cap of $6.08 billion, a PE ratio of 14.66 and a beta of 0.51. The firm’s 50 day moving average is $107.71 and its 200-day moving average is $95.52.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $378.73 million during the quarter, compared to analyst estimates of $373.58 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. As a group, analysts anticipate that Lantheus will post 5.99 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LNTH. Signaturefd LLC boosted its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC raised its holdings in Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after buying an additional 100 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares in the last quarter. Finally, Moody National Bank Trust Division increased its position in shares of Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after buying an additional 162 shares during the period. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.